67 items matched your search for "Anacor Pharmaceuticals"

Sort By: Date | Relevance
Close APPLY

Is Pfizer's Buyout of Anacor Pharmaceuticals Enough to Move the Needle?

May 16, 2016 |

newsfeedback@fool.com (George Budwell) Pfizer adds another key piece to its innovative products business today. Business > Motley Fool

Why Anacor Pharmaceuticals Sky-Rocketed 250% in 2015

January 8, 2016 |

So what: On January 7, Anacor Pharmaceuticals reported that it has filed its eczema drug, crisaborole, for FDA approval. ... In Q3, sales of Kerydin totaled $40 million, $19.1 million of which flowed through to ...

Why Anacor Pharmaceuticals Rocketed 93% Higher in July

August 5, 2015 |

Todd Campbell, The Motley Fool What: After the company reported positive top-line results from two key phase 3 studies, growing enthusiasm for drugs discovered by Anacor Pharmaceuticals' boron chemistry ...

Why Anacor Pharmaceuticals, Inc.

March 13, 2015 |

What: Shares in Anacor Pharmaceuticals  jumped by more than 15% today after reporting fourth quarter sales and earnings that eclipsed Wall Street forecasts. ... The article Why Anacor Pharmaceuticals, Inc. ...

Why Anacor Pharmaceuticals, Inc.

June 5, 2016 |

newsfeedback@fool.com (Cory Renauer) Here's what made the purveyor of novel ointments' share price skyrocket last month. Business > Motley Fool

Apple Inc. and Anacor Pharmaceuticals Inc.

May 16, 2016 |

newsfeedback@fool.com (Demitrios Kalogeropoulos) Why these two stocks broke away from stock market indexes on Monday. Business > Motley Fool

Why Anacor Pharmaceuticals Inc.

July 8, 2014 |

What: Shares of Anacor Pharmaceuticals , a biopharmaceutical company focused on developing anti-fungal and anti-inflammatory medications, briefly dipped as much as 11% this morning following the Food and Drug ...

Why Anacor Pharmaceuticals, Inc.

May 8, 2014 |

What: Shares of Anacor Pharmaceuticals, Inc. opened Thursday's trading with a 10% decline, but have recovered somewhat to a more modest 6% loss in the afternoon, after last night's release of the company's ...

Could Anacor Pharmaceuticals Shares Pop Following a Key Analyst Upgrade?

July 23, 2015 |

So what: Goldman Sachs' enthusiasm mirrors that of investors who have flocked to Anacor Pharmaceuticals shares this year. ... Goldman thinks Kerydin's sales could eventually top out at $800 million, but analysts ...

Is Now a Good Time to Sell Anacor Pharmaceuticals, Inc.?

March 20, 2014 |

This could be the case for relatively unknown biotech Anacor Pharmaceuticals . ... The article Is Now a Good Time to Sell Anacor Pharmaceuticals, Inc.? ... The Motley Fool recommends Valeant Pharmaceuticals.

Why Anacor Pharmaceuticals, Inc.'

July 13, 2015 |

George Budwell, The Motley Fool What: Shares of Anacor Pharmaceuticals  rose by over 40% today on heavy volume after the company released positive top-line results from two pivotal late-stage trials for ...

Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why

May 24, 2016 |

newsfeedback@fool.com (Sean Williams) While complimentary to its product portfolio, Pfizer's acquisition of Anacor could take a long time to pay off for shareholders.

The Top 5 Best Performing Biotech Stocks of 2015

January 2, 2016 |

Source: Anacor Pharmaceuticals, No. 4: Anacor Pharmaceuticals -- up 248%Anacor Pharmaceuticals' toenail-fungus-fighting drug Kerydin won FDA approval in July 2014, and in Q3 sales of Kerydin, which is marketed ...

Pfizer nets smaller deals

August 24, 2016 |

-based Anacor Pharmaceuticals Inc., which could get a new eczema drug, crisaborole, approved by January.

Companies That Doubled in 2015

December 24, 2015 |

Anacor Pharmaceuticals-- Up 263% Photo: Anacor Pharmaceuticals As the picture above would have you believe, Anacor is a pharmaceutical company focused on creating boron-based drug treatments. ... During July, ...

Drugmaker Pfizer decides not to break up business

September 26, 2016 |

In June, Pfizer completed a $5.2-billion acquisition of Anacor Pharmaceuticals Inc., which could get a new eczema drug, crisaborole, approved by January.

Drugmaker Pfizer decides not to break up business

September 26, 2016 |

In June, Pfizer completed a $5.2-billion acquisition of Anacor Pharmaceuticals Inc., which could get a new eczema drug, crisaborole, approved by January.

Drugmaker Pfizer decides not to break up business

September 26, 2016 |

In June, Pfizer completed a $5.2-billion acquisition of Anacor Pharmaceuticals Inc., which could get a new eczema drug, crisaborole, approved by January.

In brief: Range Resources has deal to buy Houston-based Memorial Resource Development

May 16, 2016

Pharmaceuticals Pfizer purchases skin disorder specialist TRENTON, N.J. - Pfizer is fortifying its key immunology and inflammation drug business, snapping up a small maker of skin disorder treatments for $5.2 ...

Anacor Pharma Q3 Beats on Revenues, Misses on Net

November 7, 2013 |

Eric Volkman, The Motley Fool Anacor Pharmaceuticals  is still in need of some bottom-line healing, if its Q3 results are any indication. ... The article Anacor Pharma Q3 Beats on Revenues, Misses on Net ...

PREV1 of 4 NEXT